Marker Therapeutics, Inc. — Director's Dealing 2018

Oct 18, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-10-17

Reporting Person: New Enterprise Associates 16, L.P. (10% Owner)
Reporting Person: NEA Partners 16, L.P. (10% Owner)
Reporting Person: NEA 16 GP, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant to Purchase Common Stock (right to buy)	$5.00	2023-10-17	Common Stock (3750000)		Direct

Footnotes

F1: The shares are directly held by New Enterprise Associates 16, L.P. ("NEA 16"), and indirectly held by NEA Partners 16, L.P. ("NEA Partners"), the sole general partner of NEA 16, NEA 16 GP, LLC ("NEA 16 GP"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the "Indirect Reporting Persons").The individual managers of NEA 16 GP are Peter J. Barris, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, David M. Mott, Scott D. Sandell, Peter W. Sonsini, Ravi Viswanathan and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest.